ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. See why SPRY stock is a Buy.
Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback